Disease · MONDO_0005133
Comparisons in its trials15
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 15 of 15
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Triptorelin Pamoate PR 3-month vs Triptorelin Acetate PR 1-month: deaths from any cause | 0 of 149 | 0 of 150 | 299 | NCT03232281 | Trial comparisons |
| Triptorelin Pamoate PR 3-month vs Triptorelin Acetate PR 1-month: serious adverse events | 2 of 149 | 1 of 150 | 299 | NCT03232281 | Trial comparisons |
| Elagolix vs Placebo: deaths from any cause | 0 of 131 | 0 of 69 | 200 | NCT00973973 | Trial comparisons |
| Elagolix vs Placebo: serious adverse events | 1 of 131 | 3 of 69 | 200 | NCT00973973 | Trial comparisons |
| Lower Gonadotropin Dose Stimulation vs Higher Gonadotropin Dose Stimulation: Cumulative Clinical Pregnancy Rate | 27 of 94 | 17 of 91 | 185 | NCT05103228 | Trial comparisons |
| Lower Gonadotropin Dose Stimulation vs Higher Gonadotropin Dose Stimulation: deaths from any cause | 0 of 94 | 1 of 91 | 185 | NCT05103228 | Trial comparisons |
| Lower Gonadotropin Dose Stimulation vs Higher Gonadotropin Dose Stimulation: serious adverse events | 0 of 94 | 0 of 91 | 185 | NCT05103228 | Trial comparisons |
| Intervention Group vs Placebo Group: serious adverse events | 8 of 25 | 5 of 26 | 51 | NCT00474851 | Trial comparisons |
| Tanezumab vs Placebo: serious adverse events | 0 of 22 | 3 of 25 | 47 | NCT00784693 | Trial comparisons |
| Tanezumab vs Placebo: Number of Participants With Positive Urine or Serum Pregnancy Test | 0 of 22 | 0 of 23 | 45 | NCT00784693 | Trial comparisons |
| Experimental vs Control: deaths from any cause | 0 of 5 | 0 of 4 | 9 | NCT02542410 | Trial comparisons |
| Experimental vs Control: serious adverse events | 0 of 5 | 0 of 4 | 9 | NCT02542410 | Trial comparisons |
| Low-Dose Naltrexone vs Placebo: Oxycodone Use | 0 of 5 | 0 of 4 | 9 | NCT03970330 | Trial comparisons |
| Low-Dose Naltrexone vs Placebo: deaths from any cause | 0 of 5 | 0 of 4 | 9 | NCT03970330 | Trial comparisons |
| Low-Dose Naltrexone vs Placebo: serious adverse events | 0 of 5 | 0 of 4 | 9 | NCT03970330 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005133/comparisons